MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-13-2026
Savara Operating Income 2011-2026 | SVRA
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Savara
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -124 M | -103 M | -60 M | -38.8 M | -41.5 M | -49.3 M | -79 M | -70 M | -30 M | -10.9 M | -5.92 M | -29.3 M | -21.5 M | -15.6 M | -13.4 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -5.92 M | -124 M | -46.1 M |
Quarterly Operating Income Savara
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -30.3 M | -31.4 M | -28.4 M | - | -26.4 M | -23.2 M | -22.5 M | - | -18 M | -12.2 M | -12.1 M | - | -10.5 M | -9.38 M | -8.05 M | - | -9.97 M | -10.5 M | -10.4 M | - | -10.8 M | -9.26 M | -16.2 M | -31.5 M | -12.4 M | -22.2 M | -12.9 M | -13.2 M | -12.8 M | -11.9 M | -32.1 M | -9.3 M | -6.54 M | -9.34 M | -4.77 M | -4.04 M | -3.23 M | -1.98 M | -1.69 M | -9.71 M | -39.4 M | -39.4 M | -39.4 M | -7.35 M | -7.88 M | -7.2 M | -6.84 M | -5.72 M | -5.27 M | -4.95 M | -5.59 M | -4.02 M | -3.22 M | -4.22 M | -4.17 M | -2.44 M | -3.55 M | -4.41 M | -2.99 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.69 M | -39.4 M | -12.9 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-508 M | - | 2.43 % | $ 254 M |  Germany |
 |
AbCellera Biologics
ABCL
|
-217 M | $ 3.55 | -0.28 % | $ 1.06 B |  Canada |
 |
Acorda Therapeutics
ACOR
|
-265 M | - | -24.86 % | $ 820 K |  USA |
 |
Acasti Pharma
ACST
|
-16.7 M | - | 4.01 % | $ 150 M | Canada |
 |
Adagene
ADAG
|
-36 M | $ 3.91 | -2.01 % | $ 220 M |  China |
 |
Advaxis
ADXS
|
-36.3 M | - | -9.65 % | $ 45.9 M | USA |
 |
AC Immune SA
ACIU
|
-79 M | $ 3.32 | 6.07 % | $ 229 M |  Schweiz |
 |
Aeglea BioTherapeutics
AGLE
|
-210 M | - | - | $ 1.01 B | USA |
 |
AgeX Therapeutics
AGE
|
-9.89 M | - | -10.17 % | $ 12.2 K | USA |
 |
Biophytis SA
BPTS
|
-26.8 M | - | -13.47 % | $ 169 M |  France |
 |
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
-65.1 M | - | 10.36 % | $ 9.8 M | USA |
 |
ADC Therapeutics SA
ADCT
|
-262 M | $ 4.11 | -2.61 % | $ 105 M | Schweiz |
 |
Midatech Pharma plc
MTP
|
-7 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Arcturus Therapeutics Holdings
ARCT
|
-76.3 M | $ 6.39 | -3.62 % | $ 175 M |  Israel |
 |
Adverum Biotechnologies
ADVM
|
-139 M | - | - | $ 86.2 M | USA |
 |
argenx SE
ARGX
|
-349 M | $ 706.03 | 0.39 % | $ 25 B |  Niderland |
 |
Ascendis Pharma A/S
ASND
|
-452 M | $ 228.06 | -1.28 % | $ 5 B |  Danmark |
 |
Applied Genetic Technologies Corporation
AGTC
|
-17.7 M | - | - | $ 26.5 M | USA |
 |
BioCardia
BCDA
|
-11.6 M | $ 1.28 | 0.79 % | $ 27.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
-127 M | - | - | $ 10.1 M | USA |
 |
Atea Pharmaceuticals
AVIR
|
-181 M | $ 6.13 | 1.32 % | $ 500 M | USA |
 |
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | USA |
 |
Athersys
ATHX
|
-87.1 M | - | 3.77 % | $ 22.4 M | USA |
 |
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | USA |
 |
Acer Therapeutics
ACER
|
-24.6 M | - | 2.71 % | $ 14 M | USA |
 |
ARCA biopharma
ABIO
|
-88.1 M | - | 1052.0 % | $ 415 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-8.13 M | $ 3.43 | -4.19 % | $ 7.46 B | Israel |
 |
Allena Pharmaceuticals
ALNA
|
-47.6 M | - | 3.16 % | $ 1.9 M | USA |
 |
Catalyst Biosciences
CBIO
|
11.5 M | $ 11.1 | -4.15 % | $ 992 M | USA |
 |
Aeterna Zentaris
AEZS
|
-8.67 M | - | 5.93 % | $ 314 M | Canada |
 |
AlloVir
ALVR
|
-65.4 M | - | 4.14 % | $ 49.1 M | USA |
 |
Anika Therapeutics
ANIK
|
-87.6 M | $ 14.51 | 1.04 % | $ 213 M | USA |
 |
Aptinyx
APTX
|
-62.6 M | - | -39.0 % | $ 4.57 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
-14.9 M | $ 2.26 | -7.76 % | $ 864 K | USA |
 |
AVEO Pharmaceuticals
AVEO
|
-49.6 M | - | - | $ 521 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-37.5 M | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
-7.83 M | $ 2.59 | -1.89 % | $ 16.3 M | USA |
 |
Avenue Therapeutics
ATXI
|
-11.3 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
-241 M | $ 1.51 | - | $ 385 M | Britain |
 |
BioNTech SE
BNTX
|
15.3 B | $ 94.86 | 4.77 % | $ 27.2 B | Germany |
 |
Athira Pharma
ATHA
|
-101 M | - | - | $ 269 M | USA |
 |
CureVac N.V.
CVAC
|
-412 M | - | - | $ 867 M | Germany |